
Pharma-Brief Spezial English
Some of our brochures have been translated into English: Corona pandemic, Resistant bacteria, Malaria or HIV/Aids. We would be happy if the brochures were shared among interested parties.

20. September 2022
Pharma-Brief Special 1/2022: Global Health under crisis
The Corona pandemic ignited a global health crisis. It caused care systems to collapse or brought them to the brink of their breaking point.

6. Juli 2020
Pharma-Brief Special 1/2020: Resistant pathogens
Resistant bacteria are spreading worldwide. In collaboration with partners in India, Tanzania, South Africa and Germany, we have investigated the causes and consequences of this spread.

22. November 2015
Antibiotic resistance: a global challenge (2015)
Antibiotics have been a blessing for medicine. Their discovery meant that infections which had previously caused great suffering and many deaths could now be treated.

22. November 2014
Pharma Brief Special 1/2014: Poor and forgotten
BUKO Pharma-Kampagne and HEPS Uganda have scrutinised the business behaviour of the pharma companies Bayer, Boehringer Ingelheim and Baxter in Uganda.

22. November 2012
Pharma-Brief Special 3/2012: At the expense of the poor?
BUKO Pharma-Kampagne has carefully examined the business behaviour of Bayer Health Care, Boehringer Ingelheim and Baxter in Brazil.

22. November 2011
Pharma-Brief Special 1/2011: At any price?
BUKO Pharma-Kampagne and the Institute of Public Health Bangalore/ India have made a survey of the business behavior of Bayer Health Care, Boehringer Ingelheim and Baxter in India.

29. November 2010
Pharma-Brief Special 2/2010: Malaria
Malaria is considered to be a tropical disease today. In earlier days, however, it also caused much suffering in Europe.

1. Mai 2009
Pharma-Brief Special 2/2009: AIDS
Whereas HIV/Aids is regarded as a controllable chronic disease in the western world, the situation for large parts of the world´s population is dramatic.

28. Februar 2009
Pharma-Brief Special 1/2009: Medical research: Science in the public interest
Public funding often plays a key role in research and development (R & D) of new medicines. But innovative drugs are often not affordable for people in poor countries.

29. November 2008
Pharma-Brief Special 2/2008: Tuberculosis - A social disease
The present booklet examines tuberculosis as a social disease around the turn of the 19th to the 20th century and today.

29. November 2007
Pharma-Brief Special 2/2007: Tuberculosis - A global threat
Tuberculosis (TB) is the most common infectious disease in the world. One third of the world population – around two billion people – are carriers of the mycobacterium tuberculosis.